Denali Therapeutics Inc.
DNLI
$15.49
$0.261.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 0.34% | -84.83% | |||
| Gross Profit | -0.34% | 84.83% | |||
| SG&A Expenses | 9.93% | -2.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.29% | 12.12% | |||
| Operating Income | 7.29% | -12.12% | |||
| Income Before Tax | 6.66% | -15.94% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 6.66% | -15.87% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 6.66% | -15.87% | |||
| EBIT | 7.29% | -12.12% | |||
| EBITDA | 9.17% | -10.56% | |||
| EPS Basic | 6.79% | -15.10% | |||
| Normalized Basic EPS | 9.43% | -12.50% | |||
| EPS Diluted | 6.79% | -15.10% | |||
| Normalized Diluted EPS | 9.43% | -12.50% | |||
| Average Basic Shares Outstanding | 0.13% | 0.67% | |||
| Average Diluted Shares Outstanding | 0.13% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||